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CTpathway: a CrossTalk‑based pathway
enrichment analysis method for cancer research
Haizhou Liu1†, Mengqin Yuan1†, Ramkrishna Mitra2†, Xu Zhou1, Min Long1, Wanyue Lei1, Shunheng Zhou1,
Yu‑e Huang1, Fei Hou1, Christine M. Eischen2* and Wei Jiang1*

Abstract
Background: Pathway enrichment analysis (PEA) is a common method for exploring functions of hundreds of genes
and identifying disease-risk pathways. Moreover, different pathways exert their functions through crosstalk. However,
existing PEA methods do not sufficiently integrate essential pathway features, including pathway crosstalk, molecular
interactions, and network topologies, resulting in many risk pathways that remain uninvestigated.
Methods: To overcome these limitations, we develop a new crosstalk-based PEA method, CTpathway, based on a
global pathway crosstalk map (GPCM) with >440,000 edges by combing pathways from eight resources, transcrip‑
tion factor-gene regulations, and large-scale protein-protein interactions. Integrating gene differential expression and
crosstalk effects in GPCM, we assign a risk score to genes in the GPCM and identify risk pathways enriched with the
risk genes.
Results: Analysis of >8300 expression profiles covering ten cancer tissues and blood samples indicates that CTpath‑
way outperforms the current state-of-the-art methods in identifying risk pathways with higher accuracy, reproducibil‑
ity, and speed. CTpathway recapitulates known risk pathways and exclusively identifies several previously unreported
critical pathways for individual cancer types. CTpathway also outperforms other methods in identifying risk pathways
across all cancer stages, including early-stage cancer with a small number of differentially expressed genes. Moreover,
the robust design of CTpathway enables researchers to analyze both bulk and single-cell RNA-seq profiles to predict
both cancer tissue and cell type-specific risk pathways with higher accuracy.
Conclusions: Collectively, CTpathway is a fast, accurate, and stable pathway enrichment analysis method for cancer
research that can be used to identify cancer risk pathways. The CTpathway interactive web server can be accessed
here http://www.jianglab.cn/C Tpathway/. The stand-alone program can be accessed here https://github.com/Biocc
jw/C Tpathway.
Keywords: Pathway enrichment analysis, Pathway crosstalk, Risk pathway, Molecular interaction, Network analysis
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Background
Over 15 years, significant efforts have been made to
annotate the functions of individual genes and construct higher order functional knowledgebases, such as
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
and Gene Ontology (GO) [1, 2]. However, it still remains
quite challenging to systematically interpret biological
meaning from the expression changes of thousands of
genes in a specific model system, such as disease versus
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control. To determine this, a routinely used method is the
screening of differentially expressed genes (DEGs) followed by pathway enrichment analysis (PEA).
PEA methods could be categorized into four generations [3]. First-generation methods (e.g., DAVID [4],
WebGestalt [5], and several others [6–8]) usually conduct over-representation analysis (ORA) using a hypergeometric or Fisher’s exact test to assess whether the
number of input DEGs is significantly higher than that
of the genes expected by chance. However, these ORA
methods have several limitations. Based on an arbitrary
threshold, these methods only select the DEGs that have
large expression fold changes (FC) or significant P-values
and treat each selected gene equally. Consequently, these
methods achieve highly inconsistent results with small
changes (e.g., 1.5 FC versus 2.0 FC) in thresholds.
To address these limitations, the second-generation
methods called functional class scoring (FCS) were
developed [9]. FCS methods hypothesize that even
though changes of individual genes are small in magnitude, their coordinated expression changes may have a
greater impact in modulating a pathway/gene set [10, 11].
A well-known FCS method is the gene set enrichment
analysis (GSEA) [11]. GSEA first ranks genes by differential expression FC. Enrichment scores (ESs) are then
calculated for predefined gene sets (pathways or functional gene sets) by considering how well the gene sets
are enriched at the top or bottom of the ranked gene lists,
which indicate their activation or repression, respectively. Therefore, FCS methods address the limitations of
ORA methods.
Previous studies hypothesized that genes with different topological properties have different weights for the
linked pathways [12–14]. Because topology information
of pathways was used, pathway topology-based (PT)
approaches were demonstrated to perform better than
the previous approaches and regarded as the third generation of PEA methods [15]. The method CePa calculated
the weight of a pathway node based on the network centralities [13]. SPIA considered the influence of the neighboring nodes [14]. TPEA integrated the global upstream/
downstream positions and the degrees of all nodes in
pathways [12]. A significant drawback of PT methods is
that they analyze pathways independently and neglect
pathway crosstalk, a common and critical event in biology and disease development.
From the perspective of systems biology, genes may
iteratively affect many other genes that exist in multiple pathways, causing pathway crosstalk that accounts
for the phenotypes, such as crosstalk between ERK and
WNT signaling in tumorigenesis [16]. The latest generation of the PEA method is network topology-based
(NT) approaches, which consider pathway crosstalk

Page 2 of 20

systematically in a network, such as latent pathway
identification analysis (LPIA) [17] and pathways based
on network information (PathNet) [18]. LPIA regarded
each pathway as one node to construct an edge-weighted
pathway network based on shared GO functions and
DEGs. LPIA identified pathways by random walk algorithm according to network topology. Although LPIA
considered pathway crosstalk, it ignores internal topology property within the pathway. PathNet integrated
direct evidence (gene differential expression) and indirect
evidence (neighbor gene differential expression), which
considered gene interactions in both inter- and intrapathway, as combined evidence for genes to assess their
impacts on pathways. However, the gene interactions
only depended on directed neighbors in the pathway network, and it ignored the impact of other genes.
As more biological knowledge was gained, proteinprotein interaction (PPI) network and gene expression
data were used to detect crosstalk between pathways [19,
20]. Recently, by integrating pathway information, PPI
network and gene expression data, Kelder et al. identified
indirect associations between pathways in insulin-resistant mouse liver [21]. However, in addition to PPI, transcription factor (TF) regulations also provide additional
valuable information about molecular interactions. Additionally, these methods performed enrichment analysis
mostly based on KEGG or GO, while numerous highquality pathways or functional gene sets were also publicly available, such as Reactome [22], PANTHER [23],
HumanCyc [24], INOH [25], NetPath [26], PID [27], and
WikiPathways [28]. Moreover, NT methods consume
more time and more space because of their complexity.
For example, LPIA may consume several hours for one
test. Therefore, although commonly and widely used,
current PEA methods have significant limitations, posing
barriers to discovery.
In this study, we provided a new NT method for gene
enrichment analysis called CTpathway: a crosstalk-based
PEA method in a global pathway crosstalk map (GPCM)
(Fig. 1). To obtain better speed, our method was optimized for running time to less than 1 min. Compared
with existing methods, including DAVID, GSEA, TPEA,
PathNet, and LPIA, CTpathway outperformed in terms
of accuracy, robustness, and running time. In addition,
CTpathway identified several important cancer pathways, which were not identified by other methods. Furthermore, CTpathway was useful even for data sets with
fewer DEGs. By applying CTpathway for several cancer
types of different stages (I, II, III, and IV), cancer target
pathways were identified in early-stage tissues and blood
samples. For breast cancer (BRCA) single-cell RNA-seq
(scRNA-seq) data, CTpathway could identify the cell
type-related pathways. We also developed an online web
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Fig. 1 The workflow diagram for CTpathway. a GPCM and crosstalk effect matrix construction. GPCM was constructed by integrating pathway,
TF regulation, and PPI information. Then, we evaluated the crosstalk effects in GPCM by applying the multi-RWR algorithm to calculate a crosstalk
effect matrix C. b Gene differential expression (DE) score calculation. We integrated FC and P-value to calculate DE scores. Next, risk score (RS) for
each gene and pathway score (PS) for each pathway were calculated to identify the significant risk pathways. c Visualization of significant pathways
by bar graph, bubble plot, and enrichment map

tool (http://www.jianglab.cn/CTpathway/) and the standalone program (https://github.com/Bioccjw/CTpathway)
[29], which allows users to simply upload the gene symbols or entrez gene IDs with log2FC or P-values to identify risk pathways in a specific condition (e.g., disease) by
performing the CTpathway method.

Methods
Pathway data

We collected eight knowledgebases of human pathways
including KEGG [1], PANTHER [23], Reactome [22],
HumanCyc [24], INOH [25], NetPath [26], PID [27], and
WikiPathways [28]. The interactions of gene and gene
products in pathways of Reactome, HumanCyc, INOH,

NetPath, PID, and WikiPathways were obtained from
Pathway Commons version 10 [30]. Because the information of KEGG and PANTHER in Pathway Commons
was not updated, we extracted the interactions in KEGG
and PANTHER in March 2019. For KEGG pathways, we
downloaded KGML files of 299 pathways and extracted
interaction information by iSubpathwayMiner R package [31]. For PANTHER pathways, we downloaded BioPAX files of 138 pathways, and NetPathminer R package
[32] was used to extract interaction information. For the
other six sources of pathways, we used gene interactions
in Pathway Commons. In total, we obtained 375,256
interactions, including 11,556 genes from 2563 pathways
involved in eight pathway databases (details in Table 1).
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TF‑gene regulation data

We obtained experimentally validated TF-gene regulations from the TRANSFAC Professional database
(release: February 2014) [33]. TF-gene regulations, of
which at least one node belongs to a pathway, were
retained, including 491 TFs, 1614 genes, and 4657 pairs
of regulation (Table 1).
PPI data

We obtained PPIs from 12 sources (Additional file 1:
Table S1) collected by previous researchers [34, 35]. To
obtain more reliable information, PPIs included in ≥2
sources were retained. Furthermore, we used interactions
of which at least one of the interacting nodes belongs to
a pathway. Finally, 79,262 PPIs, including 11,054 genes,
were used for the next analysis (Table 1).
Constructing a global pathway crosstalk map (GPCM)

To consider pathway enrichment more systematically, we
integrated three kinds of interactions including pathways,
PPIs, and TF regulation for constructing a GPCM to
simulate natural pathway crosstalk and adding biological
knowledge. We used the union of pathway, PPI, and TFgene information described above. For simplicity here, it
was regarded as an undirected network. In total, the network includes 15,292 nodes and 442,439 edges (details in
Table 1).
Gold standard data sets

For comparing CTpathway accuracy with other PEA
methods, we used gold standard data sets from the KEGGdzPathwaysGEO R package [36]. It contained 24 data
sets involving 12 diseases and 12 target pathways (Additional file 1: Table S2). One disease is corresponding to
one target pathway. This data set was widely used as the
gold standard for benchmarking in other methods [15,
36, 37]. In addition, to test whether CTpathway could
be applied in data sets with fewer DEGs, we analyzed 12
Table 1 Summary of data source information in GPCM
Source of interactions

#Pathways

#Genes

#Interactions

KEGG

299

5686

60,576

HumanCyc

238

1658

20,746

INOH

153

939

19,374

NetPath

27

1195

3727

PANTHER

129

2149

26,810

PID

212

2589

21,210

Reactome

1491

9990

266,500

WikiPathways

14

70

97

PPI

-

11,054

79,262

TRANSFAC

-

1947

4657

Total

2563

15,292

442,439

of 24 gold standard data sets with different numbers of
DEGs (details in Additional file 1: Table S3).
Cancer data sets from Gene Expression Omnibus (GEO)
and The Cancer Genome Atlas (TCGA) databases

To evaluate reproducibility, we used both microarray
data from the GEO database [38] and RNA-seq data from
the TCGA database [39] for each of four cancer types
(COAD, LIHC, LUAD, and OV). We downloaded eight
gene expression data of four cancer types from the GEO
database (GSE100179 [40], GSE101685 [41], GSE116959
[42], GSE9891 [43]) and TCGA database (Additional
file 1: Table S2). Each data set includes case (cancer) and
control (normal) samples (details in Additional file 1:
Table S2).
Furthermore, to test whether CTpathway could be
applied in early-stage cancer samples, we analyzed ten
data sets consisting of different cancer types available
in TCGA or GEO (GSE20189; peripheral blood samples
of LUAD patients [44]) database. Each data set includes
cancer samples of different cancer stages (I, II, III, and
IV) and normal samples (details in Additional file 1:
Table S2).
To test whether CTpathway could be applied in scRNAseq data, we downloaded breast cancer (BRCA) scRNAseq data from the GEO database (GSE118389 [45])
(Additional file 1: Table S2). The BRCA scRNA-seq data
contains 1112 cells from six triple-negative breast cancer patients. Here, we used cell type annotation results
according to the previous study [45] including B cell, T
cell, endothelial cell, epithelial cell, macrophage, and
stromal cell. More details about the data sets are shown
in Additional file 1: Table S2.
Differential expression

For the GEO microarray data set, we performed differential expression analysis by R package limma [46] to obtain
FC and P-value. For the TCGA RNA-seq data set, we
used R package DESeq2 [47] to obtain FC and P-value.
OV data differential expression profile was from a previous study [48]. For BRCA scRNA-seq data, we performed
differential expression analysis between one cell type and
the others using function "FindAllMarkers" in R package
Seurat V3.2.2 [49]. For some compared methods, which
need a set of genes as input, such as DAVID, genes with
FC > 2 or FC < 0.5 and P-value < 0.05 were used for functional enrichment analysis. For LPIA, |log2FC| value was
used as differential expression score.
Gene differential expression score

The FC and P-value are both important indexes to reflect
the differential expression level of genes. Previous studies
demonstrated that incorporating FC and P-value could
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provide significant improvement to meet the practical
needs [50, 51]. We calculated a gene differential expression
score to represent the impact of its disrupted expression on
pathways. P-value ranges from 0 to 1. In order to make the
FC value between 0 and 1, and keep genes with an FC value
with n and 1/n having the same contribution weight, the
gene differential expression score was calculated by Eq. (1).
β

1

DE =

(1 − P)α × 1 − (FC)− 2
(1 − P)α × 1 − (FC)

1
2

β

, FC ≥ 1

, 0 ≤ FC < 1

(1)

When P-value (or FC) is available or not, α (or β) equals
to 1 or 0. DE is the differential expression score, represented as a vector:


DE 1
 DE 2 
 . 
 . 
 . 
DE = 

(2)
 DE i 
 . 
 . 
.
DE L
where L is the intersection number of genes in the
expression profile and genes in the GPCM.

C11
 C21
 .
 .
 .
C=
 Ci1
 .
 .
.
CL1


C12
C22
..
.
Ci2
..
.

· · · C1j
· · · C2j
...... ..
... .
· · · Cij
...... ..
... .

CL2 · · · CLj


· · · C1N T
· · · C2N 
......
.. 

...
. 
· · · CiN 

......
.. 

...
.
· · · CLN

Here in GPCM, for one gene, we calculated a risk score
integrating all the nodes (genes) impact on this node
(gene). The GPCM was defined as a simple undirected
graph G = (V, E), where a v ∈ V represents a gene and a
e ∈ E represents an edge. First, one gene in the expression
file was taken as a seed (i.e., i), and given an initial weight
score of 1. Then, a random walk with restart (RWR) algorithm [52] was used to simulate the propagation process of
crosstalk effect Ci from one to others.

(3)

where Ci1 = Ni , r is the restart coefficient, t is iteration
times, W was a |N| × |N| column-normalized adjacent
matrix of graph G, and Ni is a |N| × 1 vector with ith
element equal to 1 and others all equal to 0. Next, with
respect to all the genes in the expression file, we iterated over each gene as a seed. This process was called a

(4)

where Cij represents the crosstalk effect of gene j
impacted by gene i. Last, we integrated C matrix and DE
vector to calculate the risk score (RS) as follows:

RS = C × DE

(5)

For example, we calculated an RS of gene j impacted by
gene i as follows:

RS ji = Cij × DE i

Risk score (RS)

Cit = r × W × Cit−1 + (1 − r) × Ni

multiple random walk with restart (multi-RWR) algorithm (Fig. 2). Here, we measured the magnitude of
change between states t and t-1 as the sum of the absolute difference of the Ct and Ct-1. The threshold was set
as 10−10 to control the iteration times. When it was less
than 10−10, the iterative computation would stop. Finally,
we obtained a crosstalk effect for all genes, named as the
crosstalk effect matrix, represented as a matrix:

(6)

where RS ji represents the risk score of gene j impacted
by gene i and DEi represents the differential expression
score of gene i.
For gene j, we integrated scores impacted by all genes
as the final gene risk score (RSj) as follows:

RS j =

L


RS ji

(7)

i=1

where L is the intersection number of genes in the
expression profile and genes in the GPCM.
The pathway enrichment score

We obtained RS of each gene in GPCM. For a pathway
k, we calculated a pathway enrichment score PSk as the
average of RS values for the genes in pathway k. The formula is as follows:

(See figure on next page.)
Fig. 2 CTpathway algorithm diagram including Multi-RWR. First, gene 1 in the expression profile was taken out as a seed and RWR was used to
obtain the crosstalk effect C1 on all nodes in the network. Next, another gene i was chosen to repeat this progress and obtained Ci. Finally, we
obtained the crosstalk effect matrix C after all genes in the profile were taken out as a seed. We also calculated the differential expression (DE) score
by integrating FC and P-value. Using both crosstalk and differential expression, we obtained the risk score RSji of gene j impacted by gene i. We
integrated the risk score of gene j impacted by all genes as gene j risk score RSj. Finally, we obtained a pathway risk score (PS) by averaging all gene
risk scores in a pathway and calculated the significance level by permutation
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n

1
PS k =
RS j
n
j=1

(8)

where n represents the number of genes in pathway k.
Identification of significant pathways

We performed the permutation analysis to estimate
the significance of the pathway. First, we shuffled genes
in the differential expression profile. Then, we calculated the pathway enrichment score for each pathway.
The background distribution was generated after performing h permutations. For a pathway, the empirical P-value was defined as the proportion of random
pathway enrichment scores (PSrandom) larger than
the real pathway

enrichment score (PS): P-value =
NPSrandom >PS 
h , where NPSrandom >PS was the number of
random pathways that had larger scores than the real
pathway. Here, h was 1000. However, because of the
limited number of permutations, it often produces a
P-value of 0. To solve this problem, we estimated the
exact P-value by using the generalized Pareto distribution (GPD) [53]. Because many pathways were involved
in this analysis, it was necessary to perform multiple
hypothesis testing methods to control the proportion
of false positives. We applied the false discovery rate
(FDR) to account for false positives [54]. The pathways
with FDR < 0.01 were considered as significant pathways. In addition, CTpathway automatically clusters
significant pathways into non-redundant groups. Pairwise similarities between any two significant pathways
are computed based on a Jaccard similarity coefficient.
According to user’s input cutoff of Jaccard similarity
coefficient, a pathway similarity network is constructed.
A default coefficient of 0.3 was set up in this study,
which could be customized by the users using our web
server. The Markov Cluster (MCL) algorithm [55] was
employed to perform clustering process. CTpathway
chooses the most significant (lowest FDR) pathway
within each cluster to represent the cluster. To obtain a
better visualization, CTpathway shows the top 20 nonredundant pathways or clusters with low FDR, if there
are more than 20 clusters or pathways. For each cluster, the top 10 pathways with lower FDR are shown in
the enrichment map if there are more than 10 pathways
which are within one cluster.


M 

Rbm − Ram 
/M
DR =
K

where Rbm represents the rank of the target pathway in
data set m before optimization and Ram represents the
rank of the target pathway in data set m after optimization. M is the number of data sets. K is the number of
total KEGG pathways. Here, M is 24 and K is 299.
DT value was calculated to represent the running time
difference (before and after optimization) as follows:

DT =

DR value was calculated to represent the rank difference
(before and after optimization) of the target pathway as
follows:

M

Tbm − Tam
/M
Tbm

(10)

m=1

where Tbm represents the running time in data set m
before the optimization, and Tam represents the running
time in data set m after the optimization.
Rank ratio (RR) value

RR value was used as the criteria to compare the accuracy
of different tools. Each data set m had an RR value for its
target pathway, represented as RRm, which was the rank
ratio of the target pathway in data set m, and calculated
as follows:

RRm =

Ram
M

(11)

where Ram and M were described as above. To make it
comparable between different methods, we used KEGG
pathways as candidate pathways.
Stability (S) value

S value was used as the criteria to compare the stability or
reproducibility of different tools. First, for eight data sets
of four cancer types, each of which has microarray data
and RNA-seq data, we identified risk pathways by using
different methods. For each cancer type, we compared
shared significant pathways identified from microarray
data and RNA-Seq data. Because compared methods just
identified few pathways or no pathways when using routine FDR or adjusted P-value as a cutoff, pathways with
P-value < 0.05 were identified as significant pathways for
all methods here. S value was calculated as follows:

S=
Rank difference (DR) and time difference (DT) values

(9)

m=1

D

Jd
d=1

D

(12)

where Jd represents the Jaccard similarity coefficient of
different data sets of cancer type d and D represents the
number of all cancer types. In this study, D is 4.
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Statistics analysis

Differential expression analysis was performed by R package limma for the GEO data set and R package DESeq2
for the TCGA data set. P-value < 0.05 was considered
to be statistically significant for DEGs. For CTpathway,
permutation analysis was performed to estimate the
significance of the pathway; FDR < 0.01 was considered
as significant. For GSEA, FDR < 0.01 was considered as
significant. For other compared methods, P-value < 0.05
was considered as significant because few pathways or
no pathways were identified when using routine FDR or
adjusted P-value as a cutoff.
Benchmarking

In this study, CTpathway was compared with five widely
used tools, including DAVID, GSEA, TPEA, LPIA, and
PathNet, in terms of accuracy, reproducibility, and running time. For accuracy, we compared RR values for each
method using 24 gold standard data sets (Additional
file 1: Table S2). For reproducibility, we compared the
S value calculated for four cancer types (COAD, LIHC,
LUAD, and OV) based on different sources (TCGA
RNA-seq data and GEO microarray data) of eight gene
expression data (Additional file 1: Table S2). For the running time, we used simulated data sets of 500, 1000, 5000,
10,000, and 20,000 genes. Because most of these methods only focused on the pathways defined in KEGG, we
used KEGG pathways for comparative analysis when
benchmarking.
Hardware platform

All benchmarks were performed on a computer with
2*Intel Xeon E5-2609 V4 Processor, 2*64G DDR4
RDIMM, 8 DIMM slots, 1*128G SSD 2.5, 1*2TB SATA
3.5, and 2*1080Ti.
Code availability

CTpathway web server is available at http://www.jianglab.
cn/CTpathway/. The CTpathway stand-alone program is
available at https://github.com/Bioccjw/CTpathway [29].
Other custom codes used in this study are available from
the corresponding authors upon reasonable request.

Results
Global pathway crosstalk map (GPCM) and its properties

By integrating three kinds of interactions including
the regulation of TFs to genes from TRANSFAC [33],
the PPIs from multiple sources in previous studies [34,
35], and the pathways from eight databases (KEGG [1],
Reactome [22], PANTHER [23], HumanCyc [49], INOH
[25], NetPath [26], PID [27], and WikiPathways [28]), we
constructed a GPCM that included 15,292 nodes and
442,439 edges (Fig. 3a and Table 1). Next, we investigated
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the topological properties of the GPCM. The degree distribution approximately displayed a power law distribution (Fig. 3b), indicating the network satisfied scale-free
topology, a general concept for biological networks.
There are some well-known signaling and transcription
factor genes with a high degree in the GPCM, such as
EGFR, AKT, MYC, and p53 (Additional file 1: Table S4).
The gene with the highest degree in the network is GNB1,
a subunit of G proteins, which are modulators or transducers in various transmembrane signaling pathways and
included in 234 pathways. In addition, we determined
that ~75% (n > 8800) of the genes participate in more
than one pathway (Fig. 3c). Density distribution of pathways showed a positively skewed distribution, which suggested that only a few pathways include a higher number
of genes (Fig. 3d). Most of the genes participate in multiple pathways, which suggest that crosstalk exists. Pathway crosstalk was represented by integrating molecular
interactions and pathways into a GPCM.
Crosstalk effect evaluation and pathway identification

Pathways are usually affected by each other in the process
of performing functions due to crosstalk [16]. We evaluated the crosstalk effects in GPCM by applying a multiRWR algorithm to calculate a crosstalk effect matrix, C,
which exploits the complete network topology (Fig. 2)
(details in the “Methods” section). Then, we integrated
FC and P-value as gene differential expression score (DE)
to reflect the disturbed level of gene expression (details
in the “Methods” section). Next, we integrated the C
matrix and differential expression score (DE) to calculate
a risk score (RS) as the impact of the gene on the pathways (Fig. 2, details in the “Methods” section). For gene
i, RSi reflects the risk score of the node i in the context
of GPCM. We further tested the relationship between RS
and |log2FC| based on a lung adenocarcinoma (LUAD)
data set (Additional file 1: Table S2) available in the GEO
database (GSE116959 [42]). Despite a higher positive correlation (Pearson correlation coefficient R ≈ 0.84) (Additional file 2: Fig. S1), we determined several known lung
cancer-associated genes with high RS and low |log2FC|
(Table 2 and Additional file 2: Fig. S1), such as TRIM28,
APP, ESR1, MYC, and EGFR [56–59]. However, these
genes would be overlooked by most of the existing PEA
methods because they only consider significant DEGs or
high |log2FC| genes.
Additionally, we questioned whether RS would reflect
gene risk better than |log2FC|. First, we downloaded cancer causal genes (CCGs) from the Cancer Gene Census
(CGC) [60]. We obtained CCGs for four cancer types
(COAD, LIHC, LUAD, and OV) separately (Additional
file 1: Tables S2 and S5). Then, we obtained two gene
expression data sets for each of these cancer types from
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Fig. 3 Overview and characteristics of the GPCM. a GPCM. Different colors represent different kinds of nodes. Gray dots represent genes from at
least two kinds of interactions (pathway, PPI, or TF regulation). b The degree distribution of GPCM. c The cumulative distribution of the number of
genes in pathways. The pie chart shows the proportion of genes in one pathway and in more than one pathway. d The density distribution of the
number of pathways

Table 2 The representative 10 genes with high RS and low |log2FC| value in LUAD (GSE116959)
Gene symbol

EntreZ ID

|log2FC| value

DE value

RS

Reference (PMID)

TRIM28

10155

0.3854

0.1186

2.3781

33091876

APP

351

0.3965

0.1244

1.4413

25502341

SP1

6667

0.2215

0.0690

1.2031

22158040

GRB2

2885

0.3315

0.1051

1.0874

26693065, 27449805

PPP1CA

5499

0.2363

0.0686

0.8904

29285244

POT1

25913

0.3106

0.0485

0.7578

19285750

ESR1

2099

0.0278

0.0013

0.7493

11929836, 16033821

MYC

4609

0.3150

0.0947

0.7396

22941188, 28089889

CDK2

1017

0.3184

0.1035

0.7185

25301183

EGFR

1956

0.0841

0.0091

0.6921

8391303, 10767376

two independent sources (TCGA and GEO, Additional
file 1: Table S2) and performed differential expression
analysis. For each data set, we ranked genes according
to their |log2FC| and RS from high to low, separately.
Next, we evaluated if CCGs were located in the top of the

rank list by the GSEA method [11]. The results showed
that CCGs were significantly located in the top of the RS
rank list for all 8 data sets at a significance level of FDR
<0.1, whereas all |log2FC|-based FDRs were >0.1 (Additional file 2: Fig. S2 and Additional file 1: Table S6). Here,
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the CCGs with low |log2FC| achieved high RS through
crosstalk with those high |log2FC| genes in GPCM. These
results indicated that RS was a better index for identifying casual genes, and thus, pathways enriched with high
RS genes are likely to have important roles. Moreover,
the proportion of risk genes in the top 100 of the RS rank
list with |log2FC| <1 varied from 17 to 60% for eight data
sets. This set of high-risk genes would have been overlooked if only considering the DEG analysis (Additional
file 2: Fig. S3).
Finally, we calculated a pathway enrichment score, PS,
by integrating the RS of all nodes in the pathway. We took
the average of the RS values in a pathway k as PSk. By permutation, we identified the significant dysregulated pathways (details in the “Methods” section).
Parameter optimization and improved performance
compared to existing tools

We tested the performance of different r values based on
24 gold standard data sets involving 12 human diseases
(Additional file 1: Table S2). In general, there was a slight
variance on the performance with different r values. In
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this study, r was set as 0.7 because CTpathway had the
best performance (Fig. 4a). In addition, we only kept
ε digits and set values smaller than 1
 0−ε to 0 for the C
matrix to improve running speed. Here, the threshold
ε was set to 3, which consequently completes the job in
less than 50 s (86.3% reduction of running time) without
compromising the quality of the results (rank difference
= 0.018) (Fig. 4b).
To illustrate the effectiveness of the proposed method
in identifying dysregulated pathways, our results were
compared with five widely used tools, including DAVID
(first-generation method) [4], GSEA (second-generation
method) [11], TPEA (third-generation method) [12],
LPIA (fourth-generation method) [17], and PathNet
(fourth-generation method) [18]. Because most of these
methods only focused on the pathways defined in KEGG,
we used KEGG pathways for this comparative analysis
(details in the “Methods” section).
First, accuracy was compared by using 24 gold standard
data sets (Additional file 1: Table S2) [36]. We compared
the RR values of the target pathways obtained from different tools (Fig. 4c). CTpathway had the significantly lower

Fig. 4 CTpathway outperforms other methods. a Box plot of target pathway RR values for different r values. b The impact of different ε values
(x-axis) on DT (left y-axis) and DR (right y-axis) values. c–f Comparative analysis of the performance of different methods in terms of accuracy (RR
and ROC curve), reproducibility, and running time, respectively. “*” represents two-sided t-test P-value < 0.05; “**” represents P-value < 0.01; “***”
represents P-value < 0.001; ns represents not significant
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RR values than other methods (no significant change
compared to PathNet), indicating that our method was
more accurate. Moreover, the comparisons of ROC
curves and AUC values also indicated CTpathway had
the best performance (Fig. 4d).
Reproducibility is also very important. Currently, most
of the PEA methods are not sufficiently reproducible
because of only using DEGs and insufficiently using pathway topology and molecular interaction information. To
evaluate the stability of the methods, we calculated the S
value (details in the “Methods” section) for four cancer
types (COAD, LIHC, LUAD, and OV) based on different sources (TCGA RNA-seq data and GEO microarray
data) of eight gene expression data sets (Additional file 1:
Table S2). The results showed that CTpathway achieved
the highest S value in all comparisons (Fig. 4e). Therefore,
our data showed that CTpathway outperformed other
tools in generating reproducible results.
Next, we compared the running time of CTpathway
with other methods such as GSEA, TPEA, PathNet, and
LPIA. Because DAVID was used on the web server, the
running time of which might be interfered by the internet
connection speed, it was excluded. We used simulated
data sets of 500, 1000, 5000, 10,000, and 20,000 genes.
Our results demonstrated that CTpathway outperformed
other methods, particularly as gene number increased.
As the number of genes rose, increased running time
was observed in TPEA, PathNet, and GSEA, whereas
no change in running time occurred in CTpathway and
LPIA (Fig. 4f ). However, LPIA running time was days
compared to CTpathway, which took less than 50 s to
analyze one set of data regardless of gene number, demonstrating that our method was independent of gene set
size. Taken together, our data show that CTpathway has
greater accuracy, higher reproducibility, and less running
time compared to other methods.
CTpathway identifies risk pathways in cancers

To demonstrate the utility of CTpathway, we firstly
applied it to eight gene expression data sets of four tumor
types (COAD, LIHC, LUAD, and OV; Additional file 1:
Table S2). In eight pathway databases, we identified significant pathways for the four tumor types at a significance level of FDR < 0.01 (Fig. 5a and b, and Additional
file 1: Table S7-S14). The number of identified pathways
in different pathway databases differed. In general, the
number of identified pathways in the Reactome database
was relatively higher because of more candidate pathways. The total number of significant pathways for the
eight gene expression data varied from approximately
300 to 500, accounting for 11.7~19.5% of all candidate
pathways (Fig. 5b). Some well-known cancer pathways
were significant in more than one cancer type (Fig. 5a

Page 11 of 20

and Additional file 1: Table S7-S14). For example, the
“AP-1 transcription factor network” was identified as a
significant pathway across four cancer types over all eight
data sets. The AP-1 transcription factor is involved in a
wide range of biological processes, such as cell growth,
proliferation, differentiation, apoptosis, migration, and
invasion [61–64]. “FOXM1 transcription factor network,”
“Degradation of the extracellular matrix,” and “Activation of matrix metalloproteinases” appeared in seven
data sets. Many previous studies have demonstrated
that these pathways are altered in multiple cancer types,
indicating their pan-cancer regulation potential [65–70].
We also identified pathways unique to a single cancer.
For example, transport-related pathways (“Transferrin
endocytosis and recycling” and “Passive transport by
Aquaporins”) were reproducibly identified in COAD in
both the GSE100179 [40] and TCGA patient cohort and
not in other cancers. Many metabolism-linked pathways
(“Pyruvate metabolism,” “Glycerolipid metabolism,” “Glycogen degradation II,” “Acetate conversion to acetyl-CoA,”
and “Caffeine metabolism”) were specifically identified in
LIHC patient cohorts in TCGA and GEO (GSE101685
[41]). Previous reports demonstrated that a large number of metabolic processes are dysregulated in LIHC to
fuel tumorigenesis [71], suggesting our method accurately identifies dysregulated pathways in cancer. Several
transcription or signal transduction-related pathways
(“RUNX1 regulates transcription of genes involved in differentiation of HSCs,” “NOTCH1 Intracellular Domain
Regulates Transcription,” “Constitutive Signaling by
NOTCH1 PEST Domain Mutants”) were shared by GEO
(GSE116959 [42]) and TCGA LUAD patient cohorts, but
not in other cancers. In OV, immune and EMT/migration/invasion-related pathways were observed, such as
“TCR,” “IL3,” “E-cadherin signaling in the nascent adherens junction,” “RUNX2 regulates genes involved in cell
migration,” “Adherens junction,” and “Stabilization and
expansion of the E-cadherin adherens junction” pathways. Importantly, these pathways have been reported to
impact cell and/or organ functions and/or tumorigenesis
[72–82]. Collectively, our results show that CTpathway
accurately identifies well-known cancer risk pathways.
Most of the pathways are previously verified known
risk pathways for the individual cancer types, indicating
CTpathway is a highly reliable tool for prioritizing the risk
pathways. Taking GEO LUAD and OV data sets as examples, all the top 10 pathways for LUAD and nine of the top
10 pathways for OV have been reported (Fig. 5c, Table 3
and Additional file 1: Table S15-S19). We also compared
risk pathways identified by different methods. We determined that all of the top 10 risk pathways for both LUAD
and OV in CTpathway were also identified by other
methods (Table 3 and Additional file 1: Table S15-S19).
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Fig. 5 CTpathway accurately identifies well-known cancer risk pathways. a The comparison of identified pathways in four cancers for eight data
sets. Gray color represents identified pathways across multiple cancer types (AC). Other colors represent cancer type-specific identified pathways.
GT represents both GEO and TCGA data sets; TS and GS represent TCGA specific and GEO specific, respectively. For cancer type-specific identified
pathways, the proportion of pathways for different data sets is shown as pie charts. b Heatmap of pathways identified for eight cancer data sets by
CTpathway in eight pathway databases. The number of candidate pathways for each database is indicated in parentheses. c The bar graph shows
the top 10 KEGG pathways

Table 3 Top 10 significant pathways identified by CTpathway based on the GSE116959 LUAD data set
FDR

Da

1.37×10−8

2.52×10−6

√

−8

ID

Pathway name

#Node

PS

P-value

hsa05200

Pathways in cancer

454

0.187

Ga

Ga

Pa

√

√
√

hsa05152

Tuberculosis

175

0.164

1.69×10

2.52×10−6

hsa05140

Leishmaniasis

72

0.233

2.58×10−8

2.57×10−6

√

√

√

hsa05133

Pertussis

52

0.239

1.03×10−7

3.09×10−6

√

√

√

hsa04110

Cell cycle

124

0.237

6.88×10−8

3.09×10−6

√

√

√

hsa04510

Focal adhesion

199

0.201

4.49×10−8

3.09×10−6

√

−8

√

hsa05166

Human T-cell leukemia virus 1 infection

233

0.196

9.77×10

3.09×10−6

√

hsa04512

Ascorbate and ECM-receptor interaction

81

0.181

8.56×10−8

3.09×10−6

√

hsa04610

Complement and coagulation cascades

55

0.171

8.71×10−8

3.09×10−6

√

hsa05150

Staphylococcus aureus infection

39

0.171

8.20×10−8

3.09×10−6

√

a

D DAVID, G GSEA, T TPEA, P PathNet, L LPIA

La

√
√
√
√
√
√
√

√

√

√
√

Liu et al. Genome Medicine

(2022) 14:118

Page 13 of 20

Table 4 Top 10 significant pathways only identified by CTpathway based on the GSE9891 OV data set
ID

Pathway name

#Node

PS

P-value

FDR

DEG proportion

hsa04072

Phospholipase D signaling pathway

118

0.096

1.44×10−7

1.65×10−6

0.025

−7

2.47×10−6

0.014

hsa04010

MAPK signaling pathway

295

0.085

3.14×10

hsa04550

Signaling pathways regulating pluripotency
of stem cells

109

0.109

7.30×10−7

5.08×10−6

0.037

hsa04310

Wnt signaling pathway

144

0.096

1.45×10−6

8.85×10−6

0.028

−6

1.11×10−5

0.053

hsa05202

Transcriptional misregulation in cancer

19

0.140

1.85×10

hsa05212

Pancreatic cancer

75

0.126

2.60×10−6

1.49×10−5

0

hsa01521

EGFR tyrosine kinase inhibitor resistance

79

0.113

4.28×10−6

2.35×10−5

0.038

hsa05225

Hepatocellular carcinoma

168

0.093

9.76×10−6

5.12×10−5

0.006

hsa04390

Hippo signaling pathway

153

0.090

1.15×10−5

5.85×10−5

0.032

hsa05224

Breast cancer

145

0.096

3.42×10−5

1.49×10−4

0.014

However, four of the top 10 pathways for LUAD or OV
were identified by only one or two existing methods
(Additional file 1: Table S15-S19), such as “Tuberculosis,”
“Focal adhesion,” and “ECM-receptor interaction,” which
play critical roles in cancer pathogenesis or progression
[83–85]. Moreover, we determined the pathways only
identified by CTpathway for OV (Table 4 and Additional
file 1: Table S17-S19), and most of these pathways were
cancer-related such as “MAPK signaling pathway” [86,
87], “Wnt signaling pathway” [88], and “Hippo signaling
pathway” [89]. We also determined that these pathways
had a lower proportion of DEG (Additional file 2: Fig.
S4). For example, CTpathway identified “MAPK signaling pathway” (Table 4), which has important roles in the
development and survival of many cancer types including
ovarian cancer [86, 87]. Also, there is a crosstalk between
“MAPK signaling pathway” and “ECM-receptor interaction” (Fig. 6a), which had been demonstrated to aid in
EMT/migration/invasion process [90–92]. Five of six
methods including CTpathway identified “ECM-receptor
interaction” as a risk pathway (Table 3); however, all of
the other compared methods were unable to determine
“MAPK signaling pathway” as a risk pathway in EMT in
OV. Furthermore, we determined that there was a lower
proportion of DEGs in the “MAPK signaling pathway”
(1.4% [4/295]) than that in the “ECM-receptor interaction” pathway (18.5% [15/81]); thus, most methods will
identify “ECM-receptor interaction” instead of “MAPK
signaling pathway.” Because the “MAPK signaling pathway” has crosstalk with “ECM-receptor interaction,” with
most DEGs (14/15) in the “ECM-receptor interaction”
having a direct connection with the “MAPK signaling
pathway,” most “MAPK signaling pathway” genes have
high RS (Fig. 6a, b). Therefore, only our method identified “MAPK signaling pathway” as a risk pathway. Moreover, we determined that, in the top 100 of the RS rank
list, there are 36 EMT genes [93], of which seven have

low |log2FC| (|log2FC| < 1) (Fig. 6c and Additional file 1:
Table S20). These genes were easily overlooked by other
methods that only considered DEGs as risk genes. Taken
together, CTpathway could identify cancer risk pathways
that were identified by existing methods, and importantly, also significant pathways and risk genes that were
overlooked by other methods.
CTpathway identifies risk pathways in data sets with fewer
DEGs

Because of its algorithmic properties, we postulated that
CTpathway would be useful for data sets with a small
number of DEGs. To test this, we screened DEGs for
24 gold standard data sets at a level of |log2FC| > 1 and
FDR < 0.1 and selected 12 representative gold standard data sets with different numbers of DEGs ranging
from 0 to 1702 (Fig. 7a and Additional file 1: Table S3).
We compared KEGG pathways identified by CTpathway with those by other five methods (DAVID, GSEA,
TPEA, PathNe, and LPIA) at a significance level of
FDR-corrected P-value < 0.05 (Fig. 7a). The number of
significant pathways identified by CTpathway was independent from the number of DEGs. For data sets with
fewer DEGs, CTpathway could identify more pathways
than all other methods. However, other methods, including DAVID, GSEA, and TPEA, showed a greater dependency on the number of DEGs. They could only identify a
small number of significant pathways for data sets with
fewer DEGs (e.g., GSE6956C [94] and GSE1297 [95]).
Furthermore, CTpathway could identify target pathways
for most (9/12) of the data sets, whereas other methods
had a lower rate of identification and overlooked them,
especially for data sets with fewer DEGs. We also compared significant pathways at a level of nominal P-value
< 0.05 (Additional file 2: Fig. S5), and CTpathway could
identify target pathways independent on the number
of DEGs. These results demonstrated that CTpathway
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Fig. 6 “MAPK signaling pathway” aid in EMT in OV. a Crosstalk between “MAPK signaling pathway” and “ECM-receptor interaction.” The red nodes
represent DEGs and the gray nodes are non-DEGs. Fourteen of 15 DEGs in the “ECM-receptor interaction” pathway have a direct connection with
the “MAPK signaling pathway.” b The risks of genes in the “MAPK signaling pathway.” Risks were measured by FC, FDR, DEG, and RS. c The bar graph
shows EMT genes in the top 100 of the RS rank list in OV

outperformed other methods for target pathway identification, particularly when there are a small number of
DEGs.
CTpathway identifies risk pathways in early‑stage cancer

Cancer diagnosis relies on detecting symptoms followed by histology/pathology evaluation. Identification of altered pathways indicative of pre-malignancy
or early-stage cancer is critical for disease prevention
and earlier treatment, leading to improved outcomes
for patients. Early-stage cancers usually show smaller
changes at the molecular level than late-stage cancers. We tested whether CTpathway could identify risk

pathways for early-stage disease in cancer patients.
First, samples of 10 cancer types that included stages I,
II, III, and IV were obtained from TCGA. We selected
the KEGG annotated ten pathways specific for the ten
cancer types (Additional file 1: Table S2). For each
cancer type of each stage, pathway enrichment analysis was performed by CTpathway and other methods.
The P-values of target pathways were compared by
different methods. The results showed that CTpathway performed better than the other methods for tissue samples (Fig. 7b, c and Additional file 2: Fig. S6).
In general, the CTpathway P-values of target pathways were smaller than those of other methods. Even
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Fig. 7 CTpathway identifies significant pathways in data sets with few DEGs and early-stage cancer patients. a The comparison of identified
pathways for data sets with a different number of DEGs in six methods. The bar graph shows the number of DEGs for 12 representative data sets.
The heatmap shows the number of significant pathways at the significance level of FDR < 0.05, identified by different methods for data sets with
a different number of DEGs, divided by the number of all candidate pathways. The target pathways are marked as green stars. b The heatmap of
enrichment results (P-value) for the target pathways of 10 early-stage cancer types using different methods. c, d Enrichment results (P-value, y-axis)
for the target pathways of TCGA COAD data sets of tissue samples (c) and LUAD blood samples (d) of different stages using different methods. The
dashed line represents a cutoff (P-value = 0.05)

in the early-stage (stage I) patients, 9/10 target pathways of cancer types could be identified by CTpathway at a significance level of P-value < 0.05, whereas
all but one other method could either not identify any
or only identified one target pathway in early-stage
patients for one cancer type (Fig. 7b). In addition,
we also evaluated blood samples, which are easier to
obtain from patients as compared to tissue samples.
CTpathway was applied to the data sets of the blood
samples (GSE20189 [44]) from LUAD patients of different stages (I, II, III, and IV), and it identified the
target pathway in the early stage as well as performed
better than the other methods across all cancer stages
(Fig. 7d). These results demonstrate that CTpathway
may be useful for early disease diagnosis.
CTpathway identifies cell type‑related pathways
in scRNA‑seq data

Due to characteristics of scRNA-seq data such as dropout events and low library sizes, the number of DEGs for

a subgroup or cell type is typically low. Because CTpathway is not limited by DEG number, we postulated it could
be utilized in scRNA-seq data. To test this, we obtained
BRCA scRNA-seq data (GSE118389 [45]). Cell types
were annotated (B cell, T cell, macrophage, endothelial cell, epithelial cell, and stromal cell) according to the
reported study [45]. Differential expression analysis was
performed between one cell type and the others by Seurat V3.2.2 [49]. Then, CTpathway was applied to each
cell type. The pathway enrichment results showed that
CTpathway could identify known cell type-related pathways in each cell type (Fig. 8). For example, “B cell receptor signaling pathway” was significant in B cell (FDR =
1.48×10−6) [96]; “Neurophilin interactions with VEGF
and VEGFR” was significant in endothelial cell (FDR
= 5.06×10−6) [97]; “Toll-like receptor signaling pathway” was significant in macrophage (FDR = 6.47×10−6)
[98]; “ECM-receptor interaction” was significant in stromal cell (FDR = 1.61×10−6) [99]; “TCR” was significant
in T cell (FDR = 6.21×10−7) [100]. Compared to other
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Fig. 8 CTpathway identifies cell type-related pathways in BRCA scRNA-seq data. The heatmap of enrichment results (PS value) of pathways in each
cell type determined by CTpathway

methods, CTpathway showed the lowest RR value for the
“B cell receptor signaling pathway” in B cell (Additional
file 2: Fig. S7). These results demonstrated that CTpathway could effectively identify cell type-related functions
or pathways in scRNA-seq data.
Reduction of pathway redundancy

Redundancy is a frequently neglected problem for most
PEA methods. Pathways sharing genes lead to functional
similarities. As a result, it is difficult to extract representative pathways from redundant information [7, 101, 102].
CTpathway automatically clusters enriched pathways into
non-redundant groups. Briefly, we constructed a similarity network after obtaining significant pathways based on
a particular cutoff of the Jaccard similarity coefficient for
shared genes among all significant pathway pairs. MCL
clustering algorithm [55] was employed to absorb most
redundancies into representative clusters. Each cluster
was renamed as the name of the most significant pathway
in this cluster. Taking TCGA COAD stage I patient samples as an example (Additional file 2: Fig. S8), we determined some clusters with two or more pathways, and our

method enables robust identification of the remaining
single node clusters, indicating that these risk pathways
reveal potentially targetable pathways, as they have the
least amount of crosstalk with other pathways. Therefore,
CTpathway is designed to obtain non-redundant pathway information to better interpret pathway enrichment
results, and this is dictated according to the needs of the
user who input a cutoff of the Jaccard similarity coefficient on the web server.
Web‑based implementation of CTpathway

We provided an online web tool for users to perform
pathway enrichment analysis with CTpathway (Additional file 2: Fig. S9). Users can input data including gene
(gene symbol or entrez ID), both log2FC and P-value
or either. By selecting several parameters, input Email
address, and clicking the “run” button (Additional file 2:
Fig. S9a and b, more details in the Web Manual page),
CTpathway returns enrichment results shown in the
table in the result page of the web server. The results
are also visualized by a bar graph, a bubble plot, and an
enrichment map (Additional file 2: Fig. S9c-e). Users can
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choose any or all results according to their needs. In the
web server, results only take a few minutes.

Discussion
PEA is a useful method for exploring gene set function. However, most existing methods did not consider
pathway crosstalk and priori knowledge. In this study,
we designed and provided to the research community
CTpathway, a crosstalk-based PEA method through a
global pathway crosstalk map (GPCM) by using multiple
sources of pathways and priori knowledge in human.
First, we collected TF-gene regulation, PPI, and genegene interaction and constructed a GPCM. The topological property analysis showed that the degree distribution
approximately displayed a power law distribution, which
was similar to most biological networks. Then, we integrated FC and P-value for each gene from differential expression analysis as gene differential expression
score (DE). Next, we obtained a crosstalk effect matrix
by the multi-RWR algorithm and calculated a final risk
score (RS) by integrating the DE and crosstalk effects.
By enrichment analysis of the CGC genes, we demonstrated that RS was a better index for identifying risk
genes, and identified important genes with a high RS
and low |log2FC| that were overlooked by other methods
that relied on |log2FC|. Finally, we calculated a pathway
enrichment score by averaging RS for genes in the pathway and identified significantly dysregulated pathways by
permutation. Our optimization process reduced ~86.3%
of the original running time. Furthermore, the performance of CTpathway is significantly better compared
with existing methods in terms of accuracy (RR and AUC
value), reproducibility, and running time. In addition, by
applying CTpathway to cancer patient samples, we determined that CTpathway could identify critical pathways,
which were not identified by other methods. For the data
sets with a small number of DEGs, CTpathway was also
useful and outperformed the other methods. Notably,
CTpathway outperformed other methods in identifying
target pathways in early-stage cancer tissues and blood
samples. For scRNA-seq data, which can have small DEG
numbers, CTpathway could effectively identify cell typerelated pathways. Our results demonstrate that CTpathway could be applied in disease analysis, and especially
for data sets with fewer DEGs, early cancer diagnosis,
which may lead to starting treatment earlier, and scRNAseq data. We also developed an online web tool to allow
users to easily and freely perform PEA with CTpathway.
This study provides a new useful PEA method, CTpathway, for over 2500 pathways in eight pathway databases,
and showed that CTpathway performed better than
other widely used methods. We evaluated CTpathway
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performance using the commonly used standard
data sets. However, these data sets are limiting because
there are only 24 target pathways for 24 diseases, indicating a need in the field for more gold standard data sets for
the evaluation of pathway enrichment analysis methods.
If the data sets contained additional known risk pathways
for diseases, the methods could be evaluated more precisely using the precision-recall curve and AUPRC. In
addition, CTpathway still has limitations related to reproducibility, which is consistent with PEA methods overall.
For example, when different data sets belonging to the
same disease serve as input, the results may differ. While
differences in samples and sample handling and processing between different labs contribute to reproducibility
challenges, CTpathway was more reproducible than the
other methods, showing ~35% overlap between different
data sets tested.
Of note, the NT methods are highly dependent on the
information of interactions, such as TF-gene regulations,
PPIs, and gene-gene interactions, and thus, incomplete
information will limit the development of these methods. In this study, TF-gene regulations come from the
TRANSFAC database. Recently, several other resources
of TF-gene regulation have been provided [103, 104].
Adding more TF-gene regulations might lead to a potential improvement of CTpathway. Notably, CTpathway
could be extended to predict non-coding RNA (ncRNA)
functions by adding ncRNA regulations or interactions into GPCM. Moreover, CTpathway only focuses
on Homo sapiens in this version. Through constructing
GPCM for other species, CTpathway could be used to
identify risk pathways of other species. Although future
studies will be needed to investigate these areas, CTpathway provides a new publicly available method that should
result in new discoveries in multiple fields of biology and
disease research.

Conclusions
This study presents a novel pathway crosstalk-based
method, CTpathway, for performing pathway enrichment
analysis. CTpathway outperformed existing methods on
accuracy, reproducibility, and speed. CTpathway exclusively identified critical pathways in several cancer types.
Furthermore, CTpathway was useful even for data sets
with few differentially expressed genes and could identify target pathways in early-stage cancer patient samples, which could lead to earlier treatment, and identify
cell type-related pathways for scRNA-seq data. Finally,
we provide an interactive and easy-to-use web server
so users can conveniently perform pathway enrichment
analysis and discover disease-risk pathways.
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